Literature DB >> 16166587

Activating Notch1 mutations in mouse models of T-ALL.

Jennifer O'Neil1, Jennifer Calvo, Keith McKenna, Veena Krishnamoorthy, Jon C Aster, Craig H Bassing, Frederick W Alt, Michelle Kelliher, A Thomas Look.   

Abstract

Recent studies have demonstrated that most patients with T-cell acute lymphocytic leukemia (T-ALL) have activating mutations in NOTCH1. We sought to determine whether these mutations are also acquired in mouse models of T-ALL. We sequenced the heterodimerization domain and the PEST domain of Notch1 in our mouse model of TAL1-induced leukemia and found that 74% of the tumors harbor activating mutations in Notch1. Cell lines derived from these tumors undergo G(0)/G(1) arrest and apoptosis when treated with a gamma-secretase inhibitor. In addition, we found activating Notch1 mutations in 31% of thymic lymphomas that occur in mice deficient for various combinations of the H2AX, Tp53, and Rag2 genes. Thus, Notch1 mutations are often acquired as a part of the molecular pathogenesis of T-ALLs that develop in mice with known predisposing genetic alterations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166587      PMCID: PMC1895623          DOI: 10.1182/blood-2005-06-2553

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Genomic instability in mice lacking histone H2AX.

Authors:  Arkady Celeste; Simone Petersen; Peter J Romanienko; Oscar Fernandez-Capetillo; Hua Tang Chen; Olga A Sedelnikova; Bernardo Reina-San-Martin; Vincenzo Coppola; Eric Meffre; Michael J Difilippantonio; Christophe Redon; Duane R Pilch; Alexandru Olaru; Michael Eckhaus; R Daniel Camerini-Otero; Lino Tessarollo; Ferenc Livak; Katia Manova; William M Bonner; Michel C Nussenzweig; André Nussenzweig
Journal:  Science       Date:  2002-04-04       Impact factor: 47.728

2.  Two distinct Notch1 mutant alleles are involved in the induction of T-cell leukemia in c-myc transgenic mice.

Authors:  C D Hoemann; N Beaulieu; L Girard; N Rebai; P Jolicoeur
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

3.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

Authors:  L B Silverman; R D Gelber; V K Dalton; B L Asselin; R D Barr; L A Clavell; C A Hurwitz; A Moghrabi; Y Samson; M A Schorin; S Arkin; L Declerck; H J Cohen; S E Sallan
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

4.  Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX.

Authors:  Craig H Bassing; Katrin F Chua; JoAnn Sekiguchi; Heikyung Suh; Scott R Whitlow; James C Fleming; Brianna C Monroe; David N Ciccone; Catherine Yan; Katerina Vlasakova; David M Livingston; David O Ferguson; Ralph Scully; Frederick W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

5.  Identification of Notch1 as a frequent target for provirus insertional mutagenesis in T-cell lymphomas induced by leukemogenic mutants of mouse mammary tumor virus.

Authors:  S Yanagawa; J S Lee; K Kakimi; Y Matsuda; T Honjo; A Ishimoto
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 6.  Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia.

Authors:  A A Ferrando; A T Look
Journal:  Semin Hematol       Date:  2000-10       Impact factor: 3.851

7.  p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice.

Authors:  J A Shank-Calvo; K Draheim; M Bhasin; M A Kelliher
Journal:  Oncogene       Date:  2006-05-18       Impact factor: 9.867

8.  A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice.

Authors:  B J Feldman; T Hampton; M L Cleary
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

9.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; Donna S Neuberg; Jane Staunton; Mignon L Loh; Christine Huard; Susana C Raimondi; Fred G Behm; Ching Hon Pui; James R Downing; D Gary Gilliland; Eric S Lander; Todd R Golub; A Thomas Look
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

10.  Notch1 signaling promotes the maturation of CD4 and CD8 SP thymocytes.

Authors:  M L Deftos; E Huang; E W Ojala; K A Forbush; M J Bevan
Journal:  Immunity       Date:  2000-07       Impact factor: 31.745

View more
  103 in total

1.  Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1.

Authors:  Todd D Ashworth; Warren S Pear; Mark Y Chiang; Stephen C Blacklow; Jérôme Mastio; Lanwei Xu; Michelle Kelliher; Philippe Kastner; Susan Chan; Jon C Aster
Journal:  Blood       Date:  2010-09-17       Impact factor: 22.113

Review 2.  Therapeutic approaches to modulating Notch signaling: current challenges and future prospects.

Authors:  Casper Groth; Mark E Fortini
Journal:  Semin Cell Dev Biol       Date:  2012-01-30       Impact factor: 7.727

Review 3.  The double-edged sword of Notch signaling in cancer.

Authors:  Andrew P South; Raymond J Cho; Jon C Aster
Journal:  Semin Cell Dev Biol       Date:  2012-01-30       Impact factor: 7.727

4.  Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphoma.

Authors:  Sarah H Beachy; Masahiro Onozawa; Yang Jo Chung; Chris Slape; Sven Bilke; Princy Francis; Marbin Pineda; Robert L Walker; Paul Meltzer; Peter D Aplan
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

5.  Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation.

Authors:  Todd A Triplett; Kim T Cardenas; Jessica N Lancaster; Zicheng Hu; Hilary J Selden; Guadalupe J Jasso; Sadhana Balasubramanyam; Kathy Chan; LiQi Li; Xi Chen; Andrea N Marcogliese; Utpal P Davé; Paul E Love; Lauren I R Ehrlich
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-09       Impact factor: 11.205

6.  Rho guanosine nucleotide exchange factors are not such bad guys after all in cancera.

Authors:  Javier Robles-Valero; L Francisco Lorenzo-Martín; Isabel Fernández-Pisonero; Xosé R Bustelo
Journal:  Small GTPases       Date:  2018-01-24

7.  Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.

Authors:  Hind Medyouf; Xiuhua Gao; Florence Armstrong; Samuel Gusscott; Qing Liu; Amanda Larson Gedman; Larry H Matherly; Kirk R Schultz; Francoise Pflumio; Mingjian James You; Andrew P Weng
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

Review 8.  Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.

Authors:  Yulia Nefedova; Dmitry Gabrilovich
Journal:  Drug Resist Updat       Date:  2008-10-31       Impact factor: 18.500

9.  Heterozygosity for hypoxia inducible factor 1alpha decreases the incidence of thymic lymphomas in a p53 mutant mouse model.

Authors:  Jessica A Bertout; Shetal A Patel; Benjamin H Fryer; Amy C Durham; Kelly L Covello; Kenneth P Olive; Michael H Goldschmidt; M Celeste Simon
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

10.  K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Authors:  Thomas Kindler; Melanie G Cornejo; Claudia Scholl; Jianing Liu; Dena S Leeman; J Erika Haydu; Stefan Fröhling; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.